GC
ABVX icon

Guggenheim Capital’s Abivax ABVX Stock Holding History

Guggenheim Capital’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.28M Sell
24,583
-491
-2% -$55.6K 0.02% 576
2026
Q1 		$2.79M Sell
25,074
-12
-0% -$1.42K 0.02% 605
2025
Q4 		$3.38M Buy
25,086
+7,828
+45% +$854K 0.02% 534
2025
Q3 		$1.47M Buy
17,258
+1,161
+7% +$71.2K 0.01% 788
2025
Q2 		$123K Buy
16,097
+2,305
+17% +$15K ﹤0.01% 1550
2025
Q1 		$86.2K Buy
13,792
+1,280
+10% +$8.66K ﹤0.01% 1612
2024
Q4 		$91.6K Buy
+12,512
New +$115K ﹤0.01% 1662

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Guggenheim Capital's ABVX Position: Q2 2026 in Review

Guggenheim Capital reduced its Abivax (ABVX) stake by 2% in Q2 2026, selling an estimated $55.6K and leaving 24,583 shares worth $3.28M. The position accounts for 0.02% of the portfolio, ranked #576.

Guggenheim Capital first reported a position in ABVX in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.38M in Q4 2025. 304 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Guggenheim Capital held 24,583 shares of Abivax worth $3.28M as of Q2 2026.
  • Guggenheim Capital sold 491 Abivax shares in Q2 2026, an estimated $55.6K.
  • Abivax made up 0.02% of Guggenheim Capital's portfolio in Q2 2026, its #576 holding.
  • Guggenheim Capital first reported a position in Abivax in Q4 2024 and has held it in 7 quarters since.
  • Guggenheim Capital's Abivax position peaked at $3.38M in Q4 2025.
  • 304 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.